Themen: Forschung

Improvement of metabolic syndrome with formoline L112

15. Oktober 2025 09:00

Abstract
Metabolic syndrome (MS) is one of the major risk factors for the development of diabetes mellitus type 2 and cardiovascular disease. Polyglucosamine L112 (formoline L112) is a high-effective-weight fat binder whose efficacy in weight reduction has been demonstrated in a randomized, double-blind, placebo-controlled study (POSO II, 2023) (4). A recent subgroup analysis (2025) investigate

Influence of Chitosan Treatment on Surrogate Serum Markers of Cholesterol Metabolism in Obese Subjects

11. Januar 2018 00:00

Dieter Lütjohann (1*), Milka Marinova (2), Karsten Wolter (2), Winfried Willinek (2,3), Norman Bitterlich (4), Martin Coenen (1), Christoph Coch (1) and Frans Stellaard (1)
1 Institute for Clinical Chemistry and Clinical Pharmacology, University Clinics of Bonn, D-53127 Bonn, Germany; martin.coenen@ukb.uni-bonn.de (M.C.); ccoch@uni-bonn.de (C.C.); fstellaard@hotmail.com (F.S.)
2 Department o